The clinical investigator

, Volume 70, Issue 7, pp 566–572 | Cite as

Testosterone treatment of men with idiopathic hemochromatosis

  • H. K. Kley
  • W. Stremmel
  • J. B. Kley
  • R. Schlaghecke
Original Article


Patients with chronic liver disease usually exhibit low plasma levels of testosterone with loss of libido and potency; this is also valid in male patients suffering from idiopathic hemochromatosis (IHC), in whom nowadays the diagnosis is made at an earlier age. Therefore, the effect of testosterone treatment was studied in 10 patients with IHC. After the application of 250 mg testosterone enanthate i.m., the plasma testosterone (from 2.4±1.9 to 20.1±7.4 ng/ml) and estradiol (from 17.4±6.3 to 38.5±14.2 pg/ml) levels increased significantly. The rise of estradiol was in the range of controls and smaller than reported in other chronic liver diseases. In a long-term study, 250 mg testosterone enanthate was given 4-weekly for 33–96 months to 5 patients with IHC. General well-being, libido, and potency recovered almost immediately. Over a treatment period of 27.3 patient years, symptoms of hyperestrogenism (gynecomastia) or (portal vein) thrombosis were not seen, both of which had been described in patients with alcoholic liver cirrhosis. There was no deterioration of liver function. The effect of testosterone treatment on the patients' well-being and plasma hormone concentrations remained unchanged over the whole period of testosterone treatment. Thus, in male patients with IHC and lowered plasma testosterone, treatment with testosterone enanthate may be instituted. Because of the positive effects on general well-being, liver regeneration capacity, and potency, testosterone should especially be administered to younger subjects suffering from IHC.

Key words

Idiopathic hemochromatosis Testosterone treatment Plasma testosterone Plasma estradiol Sexual hormone binding globulin 



idiopathic hemochromatosis


luteinizing hormone


sexual hormone binding globulin


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Charbonnel B, Chupin M, LeGrand A, Guillon J (1981) Pituitary function in idiopathic haemochromatosis: hormonal study in 36 male patients. Acta Endocrinol (Copenh) 98:178–181Google Scholar
  2. 2.
    Chopra IJ, Tulchinsky D, Greenway FL (1973) Estrogen-androgen imbalance in hepatic cirrhosis. Ann Intern Med 79:198–203Google Scholar
  3. 3.
    Doe RP, Mellinger GT, Swaim WR, Seal US (1967) Estrogen dosage effects on serum proteins: a longitudinal study. J Clin Endocrinol Metab 27:1081–1088Google Scholar
  4. 4.
    Dorfmann H, Solnica J, Mitrovic D, Dreyfuß P (1969) Veränderungen an Knochen und Gelenken bei der Hämochromatose. Münch Med Wochenschr 11:1396–1399Google Scholar
  5. 5.
    Gluud C, Bennett P, Dietrichson O, Johnsen SG, Ranek L, Svendsen LB, Juhl E (1981) Short-term parenteral and peroral testosterone administration in men with alcoholic cirrhosis. Scand J Gastroenterol 16:749–755Google Scholar
  6. 6.
    Gordon GG, Olivo J, Rafii F, Southren AL (1975) Conversion of androgens to estrogens in cirrhosis of the liver. J Clin Endocrinol Metab 40:1018–1026Google Scholar
  7. 7.
    Henke F, Lubarsch O (1966) Drüsen mit innerer Sekretion. (Handbuch der Speziellen Pathologischen Anatomie und Histologic, vol 8) Springer, Berlin Heidelberg New York, pp 950–961Google Scholar
  8. 8.
    Jabbari M, Leevy CM (1967) Protein anabolism and fatty liver of the alcoholic. Medicine (Baltimore) 46:131–139Google Scholar
  9. 9.
    Johnson FL, Feagler JR, Leber KG (1972) Association of androgenic-anabolic steroid therapy with the development of hepatocellular carcinoma. Lancet II: 1273–1276Google Scholar
  10. 10.
    Johnson SG, Kampmann JP, Bennett EP, Schonau-Jorgensen F (1976) Enzyme induction by oral testosterone. Clin Pharmacol Ther 20:233–237Google Scholar
  11. 11.
    Kley HK, Krüskemper HL (1977) Leber und Steroid-hormone. Med Klin 71:231–239Google Scholar
  12. 12.
    Kley HK, Herrmann J, Morgner KD, Kruskemper HL (1973) Effects of testosteroneoenanthate on plasma concentrations of thyroxine, cortisol, testosterone and hormone binding proteins in patients with hypogonadism. Horm Metab Res 5:271–275Google Scholar
  13. 13.
    Kley HK, Nieschlag E, Bidlingmaier F, Kruskemper HL (1974) Possible age-dependent influence of oestrogens on the binding of testosterone in plasma of adult men. Horm Metab Res 6:213–216Google Scholar
  14. 14.
    Kley HK, Nieschlag E, Wiegelmann W, Kruskemper HL (1975) Steroid hormones and their binding in plasma of male patients with fatty liver, chronic hepatitis and liver cirrhosis. Acta Endocrinol (Copenh) 79:275–285Google Scholar
  15. 15.
    Kley HK, Keck E, Kruskemper HL (1976) Estrone and estradiol in patients with cirrhosis of the liver: effects of ACTH and dexamethasone. J Clin Endocrinol Metab 43:557–560Google Scholar
  16. 16.
    Kley HK, Strohmeyer G, Kruskemper HL (1979) Effect of testosterone application on hormone concentrations of androgens and estrogens in male patients with cirrhosis of the liver. Gastroenterology 76:235–241Google Scholar
  17. 17.
    Kley HK, Solbach HG, McKinnan JC, Kruskemper HL (1979) Testosterone decrease and oestrogen increase in male patients with obesity. Acta Endocrinol (Copenh) 91:553–563Google Scholar
  18. 18.
    Kley HK, Stremmel W, Niederau C, Hehrmann R, Shams O, Strohmeyer G, Kruskemper HL (1985) Androgen and estrogen response to adrenal and gonadal stimulation in idiopathic hemochromatosis: evidence for decreased estrogen formation. Hepatology 5:251–256Google Scholar
  19. 19.
    Kley HK, Niederau C, Stremmel W, Lax R, Strohmeyer G, Krüskemper HL (1985) Conversion of androgens to estrogens in idiopathic hemochromatosis: comparison with alcoholic liver cirrhosis. J Clin Endocrinol Metab 61:1–6Google Scholar
  20. 20.
    Leevy CM (1967) Clinical diagnosis, evaluation and treatment of liver disease in alcoholics. Fed Proc 26:1474–1481Google Scholar
  21. 21.
    Lester R, Eagon PK, Van Thiel DH (1979) Feminization of the alcoholic: the estrogen/testosterone ratio. Gastroenterology 76:415–417Google Scholar
  22. 22.
    Mendenhall CL, Anderson S, Garcia-Pont P (1984) Shortterm and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 311:1464–1470Google Scholar
  23. 23.
    Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G (1985) Survival and causes of death in cirrhotic and noncirrhotic patients with primary hemochromatosis. N Engl J Med 313:1256–1262Google Scholar
  24. 24.
    Stocks AE, Powell LW (1972) Pituitary function in idiopathic haemochromatosis and cirrhosis of the liver. Lancet 11:298–300Google Scholar
  25. 25.
    The Copenhagen Study Group for Liver Diseases (1986) Testosterone treatment of men with alcoholic cirrhosis: a double-blind study. Hepatology 6:807–813Google Scholar
  26. 26.
    Van Thiel DH, Lester R, Sherins RJ (1974) Hypogonadism in alcoholic liver disease: evidence for a double defect. Gastroenterology 67:1188–1199Google Scholar
  27. 27.
    Walsh CH, Wright AC, Williams JW, Holder G (1976) A study of pituitary function in patients with idiopathic hemochromatosis. J Clin Endocrinol Metab 43:866–872Google Scholar
  28. 28.
    Wardle EW, Patton JT (1969) Bone and joint changes in haemochromatosis. Ann Rheum 28:15–21Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • H. K. Kley
    • 1
    • 3
  • W. Stremmel
    • 2
  • J. B. Kley
    • 2
  • R. Schlaghecke
    • 2
  1. 1.Städtisches Krankenhaus, Singen/HohentwielGermany
  2. 2.Medizinische Klinik C and D der Heinrich-Heine-UniversitätDüsseldorf
  3. 3.Medizinische Klinik Städtisches KrankenhausSingenFRG

Personalised recommendations